Literature DB >> 1346752

Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group.

L M Aledort1, M W Hilgartner, M C Pike, G F Gjerset, M A Koerper, E Y Lian, J M Lusher, J W Mosley.   

Abstract

OBJECTIVE--To examine the CD4 count and its near term changes relative to progression to AIDS within 30 months and to subsequent CD4 counts. DESIGN--Longitudinal clinical and laboratory study. SETTING--Haemophilia treatment centres in six large American cities. PATIENTS--555 people with congenital clotting disorders who were infected with HIV, initially without AIDS, and seen at follow up for 6-30 months in 1986-9. MAIN OUTCOME MEASURES--Absolute CD4 counts and incidence of AIDS. RESULTS--Outset CD4 count and age were independently related to progression to AIDS (p less than 0.0001 and p less than 0.005 respectively). Patients with CD4 counts of 0.30-0.49 x 10(9) cells/l had an age adjusted risk of AIDS within 30 months of only 9% that of patients with counts less than 0.20 x 10(9)/l. Children under 10 years old had only 16% of the CD4 adjusted risk of AIDS of people aged greater than or equal to 45 years. Analysis of 149 patients' CD4 counts at the beginning and end of two successive six month intervals showed an average decrease of 11% in each six months regardless of the outset count (greater than or equal to 0.20 x 10(9)/l). For individual patients the decrease in the second six month period was unaffected by the decrease in the first six month period. CONCLUSIONS--Antiviral treatment of asymptomatic people, particularly children, with CD4 counts greater than or equal to 0.3 x 10(9)/l is questionable if predicted on near term progression to AIDS. Because of individual CD4 count variability and the low rate of progression to AIDS near term declines in individual CD4 counts are a poor index for identifying people who will rapidly progress to AIDS.

Entities:  

Mesh:

Year:  1992        PMID: 1346752      PMCID: PMC1881487          DOI: 10.1136/bmj.304.6821.212

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  24 in total

1.  Half-dose zidovudine.

Authors:  P de Truchis; D Salmon; S Matheron; P Jelasko; W Rozenbaum; C Leport
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

2.  Early treatment for HIV: the time has come.

Authors:  G H Friedland
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

3.  Trend and homogeneity analyses of proportions and life table data.

Authors:  D G Thomas; N Breslow; J J Gart
Journal:  Comput Biomed Res       Date:  1977-08

Review 4.  How can epidemiology assist in guiding interventions for the acquired immunodeficiency syndrome/human immunodeficiency virus?

Authors:  S H Vermund; D F Hoth
Journal:  Ann Epidemiol       Date:  1990-12       Impact factor: 3.797

5.  Immune activation markers and AIDS prognosis.

Authors:  D H Osmond; S Shiboski; P Bacchetti; E E Winger; A R Moss
Journal:  AIDS       Date:  1991-05       Impact factor: 4.177

6.  Serial CD4 lymphocyte counts and development of AIDS.

Authors:  A N Phillips; C A Lee; J Elford; G Janossy; A Timms; M Bofill; P B Kernoff
Journal:  Lancet       Date:  1991-02-16       Impact factor: 79.321

7.  Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age.

Authors:  M E Eyster; M H Gail; J O Ballard; H Al-Mondhiry; J J Goedert
Journal:  Ann Intern Med       Date:  1987-07       Impact factor: 25.391

8.  Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort.

Authors:  R J Cuthbert; C A Ludlam; J Tucker; C M Steel; D Beatson; S Rebus; J F Peutherer
Journal:  BMJ       Date:  1990-10-27

9.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

View more
  6 in total

1.  Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS?

Authors:  D R Bainbridge; M W Lowdell; I M Hannet; K W Strauss; A Karpas
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-07-29       Impact factor: 6.237

2.  When should asymptomatic patients with HIV infection be treated with zidovudine?

Authors:  B G Gazzard
Journal:  BMJ       Date:  1992-02-22

3.  Serum 27E10 antigen: a new potential marker for staging HIV disease.

Authors:  N Lügering; R Stoll; T Kucharzik; G Burmeister; C Sorg; W Domschke
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

4.  Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.

Authors:  Marcel Wolbers; Abdel Babiker; Caroline Sabin; Jim Young; Maria Dorrucci; Geneviève Chêne; Cristina Mussini; Kholoud Porter; Heiner C Bucher
Journal:  PLoS Med       Date:  2010-02-23       Impact factor: 11.069

5.  HIV infection in haemophilia--a European cohort.

Authors:  A Aronstam; B Congard; D I Evans; C F Gazengel; U Herberg; F G Hill; P M Jones; R Ljung; E P Mauser-Bunschoten; E Scheibel
Journal:  Arch Dis Child       Date:  1993-04       Impact factor: 3.791

Review 6.  Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).

Authors:  R Whittington; R N Brogden
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.